Did LL cure Acinetobacter baumannii during covid..
Post# of 151807
(Total Views: 696)
Posted On: 04/05/2025 12:39:43 AM
Did LL cure Acinetobacter baumannii during covid...
From a Covid report: Respiratory tract infections were the most common during ECMO treatment, and the main pathogen was Acinetobacter baumannii.
CDC: Acinetobacter baumannii can cause infections in the blood, urinary tract, lungs (pneumonia) or wounds.
Leronlimab was the only drug in the world that took very long term covid people off ECMO @ 14 days & here's just 1 other:
https://pmc.ncbi.nlm.nih.gov/articles/PMC7985604/
Risk factors for A. baumannii infection include admission to the ICU, advanced age, immunosuppression, intravascular devices, invasive procedures, malignancies, mechanical ventilation, prior colonization, prolonged hospital stay, recent surgery, and severity of illness"
Leronlimab definitely checks a few of those boxes.
Cytodyn March 09, 2020: “Coronavirus deaths are linked to patients’ immune systems that have an inflammatory response to the virus causing Acute Respiratory Distress Syndrome (ARDS). With ARDS, the entire lung is affected, unlike pneumonia where often only part of the lung is affected,” --- Aka: our cytokine storm blitz from back then.
Acinetobacter baumannii is a leading cause of hospital-acquired infections (HAIs), particularly in intensive care units (ICUs), and is associated with high mortality rates.
Antimicrobial Resistance:
A major concern is the increasing prevalence of multidrug-resistant A. baumannii (MDR-AB) and carbapenem-resistant A. baumannii (CRAB), which makes infections difficult to treat.
Mortality Rates:
Studies have shown that mortality rates can be as high as 35% to 84.3% in patients with MDR-AB infections, especially those in ICUs.
In a study, the 30-day mortality rate associated with A. baumannii infection was 71.2%.
In another study, 14-day mortality was observed in 26.1% of patients and 30-day mortality in 30.9% of the patients.
& Acinetobacter baumannii kills 50% more people than Sepis. ( Google info )
Odds are Leronlimab also defeated Acinetobacter baumannii pneumonia during covid. With Ab being the fastest mortality rate Leronlimab has defeated to date.
Diagnosed with Acinetobacter baumannii:
Leronlimab combo for Acinetobacter baumannii to see if can help in the Antimicrobial Resistance fight.
Just like with chemo.
From a Covid report: Respiratory tract infections were the most common during ECMO treatment, and the main pathogen was Acinetobacter baumannii.
CDC: Acinetobacter baumannii can cause infections in the blood, urinary tract, lungs (pneumonia) or wounds.
Leronlimab was the only drug in the world that took very long term covid people off ECMO @ 14 days & here's just 1 other:
https://pmc.ncbi.nlm.nih.gov/articles/PMC7985604/
Risk factors for A. baumannii infection include admission to the ICU, advanced age, immunosuppression, intravascular devices, invasive procedures, malignancies, mechanical ventilation, prior colonization, prolonged hospital stay, recent surgery, and severity of illness"
Leronlimab definitely checks a few of those boxes.
Cytodyn March 09, 2020: “Coronavirus deaths are linked to patients’ immune systems that have an inflammatory response to the virus causing Acute Respiratory Distress Syndrome (ARDS). With ARDS, the entire lung is affected, unlike pneumonia where often only part of the lung is affected,” --- Aka: our cytokine storm blitz from back then.
Acinetobacter baumannii is a leading cause of hospital-acquired infections (HAIs), particularly in intensive care units (ICUs), and is associated with high mortality rates.
Antimicrobial Resistance:
A major concern is the increasing prevalence of multidrug-resistant A. baumannii (MDR-AB) and carbapenem-resistant A. baumannii (CRAB), which makes infections difficult to treat.
Mortality Rates:
Studies have shown that mortality rates can be as high as 35% to 84.3% in patients with MDR-AB infections, especially those in ICUs.
In a study, the 30-day mortality rate associated with A. baumannii infection was 71.2%.
In another study, 14-day mortality was observed in 26.1% of patients and 30-day mortality in 30.9% of the patients.
& Acinetobacter baumannii kills 50% more people than Sepis. ( Google info )
Odds are Leronlimab also defeated Acinetobacter baumannii pneumonia during covid. With Ab being the fastest mortality rate Leronlimab has defeated to date.
Diagnosed with Acinetobacter baumannii:
Leronlimab combo for Acinetobacter baumannii to see if can help in the Antimicrobial Resistance fight.
Just like with chemo.
(7)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼